Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY: RCUS )

13.10 +0.40 (+3.15%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
From Arcus Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Oncternal Therapeutics (NASDAQ:ONCT 
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
From Arcus Biosciences, Inc.
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
Why Arcus Biosciences Stock Vaulted Higher in November
Arcus was one of the few winners in the turbulent biotech space last month. 
Via The Motley Fool
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
From Arcus Biosciences, Inc.
Via Business Wire
Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
From Arcus Biosciences, Inc.
Via Business Wire
54 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company... 
Via Benzinga
Exposures Product Safety
Arcus Stock Rockets To Record As Gilead Unexpectedly Opts Into Cancer Drugs
Gilead opted into three programs from a small biotech company, sending shares flying. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the... 
Via Benzinga
Exposures Product Safety
Why Are Arcus Biosciences Shares Trading Higher Today?
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT... 
Via Benzinga
Why Arcus Biosciences Stock Is On Fire Today
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) stock increased by 78.28% to $37.94 during Thursday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
From Gilead Sciences, Inc.
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
Recap: Arcus Biosciences Q3 Earnings
Arcus Biosciences (NYSE:RCUS) reported its Q3 earnings results on Monday, November 8, 2021 at 04:10 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
From Arcus Biosciences, Inc.
Via Business Wire
Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights
From Arcus Biosciences, Inc.
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
Arcus Biosciences to Participate at Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.